PTC Therapeutics: This Current Report On Form 8k And Exhibits 99.1 And 99.2 Include A Forwardlooking Financial Measure That Was Not Prepared In Accordance With Accounting Principles Generally Accepted In The United States (gaap), Nongaap R&d And Sg&a Expenses (which Excludes Noncash Stockbased Compensation Expense). Management Uses This Measure When Assessing And Identifying Operational Trends And, In Management’s Opinion, This Nongaap Measure Is Useful To Investors And Other Users Of Its Financial Statements By Providing Greater Transparency Into The Historical And Projected Operating Performance Of The Company And The Company’s Future Outlook. Nongaap Financial Measures Are Not An Alternative For Financial Measures Prepared In Accordance With Gaap

Show full article

This functionality is available for registred users only

• Full name
  PTC Therapeutics, Inc.
• Registration country
  USA
• Industry
  Pharmaceutical Preparation and Biotechnology
• М/S&P/F
  *** / *** / ***